stoxline Quote Chart Rank Option Currency Glossary
Nuvation Bio Inc. (NUVB)
2.92  -0.01 (-0.34%)    06-18 12:27
Open: 2.9
High: 2.94
Volume: 282,615
Pre. Close: 2.93
Low: 2.845
Market Cap: 722(M)
Technical analysis
2024-06-18 11:52:15 AM
Short term     
Mid term     
Targets 6-month :  3.7 1-year :  4.14
Resists First :  3.17 Second :  3.54
Pivot price 2.88
Supports First :  2.56 Second :  2.13
MAs MA(5) :  2.94 MA(20) :  2.95
MA(100) :  2.61 MA(250) :  1.94
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  53.8 D(3) :  55.5
RSI RSI(14): 46.2
52-week High :  4.15 Low :  0.94
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ NUVB ] has closed above bottom band by 47.5%. Bollinger Bands are 47.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.04 - 3.06 3.06 - 3.07
Low: 2.87 - 2.89 2.89 - 2.9
Close: 2.9 - 2.93 2.93 - 2.95
Company Description

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.

Headline News

Sun, 16 Jun 2024
Octagon Capital Advisors LP Takes $1.51 Million Position in Nuvation Bio Inc. (NYSE:NUVB) - Defense World

Sat, 15 Jun 2024
Octagon Capital Advisors LP Takes $1.51 Million Position in Nuvation Bio Inc. (NYSE:NUVB) - MarketBeat

Fri, 14 Jun 2024
Nuvation Bio Inc. (NYSE:NUVB) Director Kim D. Blickenstaff Acquires 172189 Shares - Defense World

Thu, 13 Jun 2024
Nuvation Bio Inc. (NYSE:NUVB) Director Acquires $499,348.10 in Stock - MarketBeat

Tue, 11 Jun 2024
Institutional investors control 42% of Nuvation Bio Inc. (NYSE:NUVB) and were rewarded last week after stock increased 11% - Simply Wall St

Wed, 29 May 2024
Nuvation Bio to Present at the Jefferies Global Healthcare Conference - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 247 (M)
Shares Float 147 (M)
Held by Insiders 27.2 (%)
Held by Institutions 52.8 (%)
Shares Short 3,310 (K)
Shares Short P.Month 3,190 (K)
Stock Financials
EPS -0.32
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.71
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -9.2 %
Return on Equity (ttm) -11.2 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.38
Qtrly Earnings Growth 0 %
Operating Cash Flow -64 (M)
Levered Free Cash Flow -41 (M)
Stock Valuations
PE Ratio -8.99
PEG Ratio 0
Price to Book value 1.06
Price to Sales 0
Price to Cash Flow -11.04
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android